OPK earnings call summary

Prepared Highlights

• Diagnostics segment revenue: Q2 2025 was $101.1 million (including $24.9 million from oncology assets being sold), down from $129.4 million in Q2 2024, primarily due to the prior Labcorp transaction (CFO).
• Diagnostics operating loss: improved to $18.2 million in Q2 2025 from $26.6 million in Q2 2024 (CFO).
• Diagnostics cost savings: annualized cost savings of ~$19 million from latest reduction in force and footprint consolidation; post-oncology transaction, expected to deliver over $25 million in annualized cost savings (IR, CFO).
• BioReference testing volume: excluding pending and closed asset sales, grew 1.4% in Q2 2025 vs. Q2 2024 (IR).
• 4Kscore test volume: year-over-year increase of ~12% in Q2 2025; FDA granted supplemental approval on July 25, 2025, enabling use without digital rectal examination information (IR).
• Pharmaceutical segment revenue: Q2 2025 was $55.7 million, up from $52.8 million in Q2 2024 (CFO).
• Pharmaceutical operating loss: $28.7 million in Q2 2025 vs. $24.8 million in Q2 2024, driven by increased R&D investments (CFO).
• R&D spending: $29.8 million in Q2 2025, up from $23.7 million in Q2 2024, primarily for ModeX development programs (CFO).
• Consolidated operating loss: $60 million in Q2 2025 vs. $61.7 million in Q2 2024 (CFO).
• Net loss: Q2 2025 was $148.4 million ($0.19 per share) vs. $10.3 million ($0.01 per share) in Q2 2024, including ~$92 million expense from convertible note exchange (CFO).
• Cash position: $285 million in cash, cash equivalents and restricted cash at quarter end (CFO).
• Share repurchase: repurchased ~13.6 million shares in Q2 2025; $141.5 million remaining capacity under $200 million program as of June 30 (CEO, CFO).
• Capital allocation: invested ~$8 million into Entera Bio related to oral GLP-1 program (CFO).
• Oncology transaction: expected to close near end of Q3 2025; $192.5 million payable at closing, with earn-out up to $32.5 million based on retained client accounts (IR).
• Post-transaction BioReference: remaining core clinical testing operations revenue represented ~$300 million in 2024; headcount expected to decrease to 1,450–1,500 by Q4 2025 (IR).
• ModeX pipeline: MDX2001 tetraspecific T cell engager progressed to fifth dose level in Phase I; 2 additional programs (MDX2003, MDX2004) expected to enter clinic late 2025/early 2026 (IR).
• EBV vaccine: Phase I trial by Merck evaluating up to 200 healthy adults; results will guide Phase II decisions (CEO, IR).
• BARDA funding: $59 million in 2024 and $51 million so far in 2025 for infectious disease antibody programs (IR).
• OPK-88006 (GLP-1/glucagon agonist): preclinical data presented at ADA and ENDO meetings; oral version in pre-IND stage with Entera Bio (CEO, IR).
• NGENLA: Pfizer profit share was $6.1 million in Q2 2025 vs. $6.3 million in Q2 2024; NGENLA holds ~1/3 of global long-acting hGH market (CFO).

Official guidance (full-year 2025):

• Total revenue: $640M–$660M
• Revenue from services: $405M–$425M (including $95M–$105M from oncology assets)
• Revenue from products: $160M–$170M
• Other revenue: $65M–$75M (including Pfizer profit share $28M–$35M, BARDA support $30M–$35M)
• Total costs and expenses: $835M–$865M (excluding $15M–$20M onetime restructuring costs)
• R&D spending: $120M–$130M (partially offset by $30M–$35M BARDA funding)
• Depreciation and amortization: ~$90M
• Expected $100M gain on oncology transaction (CFO)

Management quotes:

• "We have streamlined BioReference Health's operations as we prepare to close the sale of its oncology and related clinical testing business to Labcorp." (CEO)
• "Post transaction, BioReference will maintain its core clinical testing operations in New York and New Jersey, and will continue to offer urology diagnostic services, highlighting our proprietary 4Kscore test." (IR)
• "We are also pleased to announce that on July 25, the FDA granted approval of a supplemental application for the 4Kscore test." (IR)
• "We remain on track to achieve cash flow breakeven and positive cash from operations in 2025." (CFO)
• "We are confident that the restructuring efforts we're undertaking will position BioReference to be more efficient and profitable following the completion of the second asset sale." (IR)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — James D Stamos

• Topic: NGENLA profit-share trend & Diagnostics EBITDA margin outlook
• Key points:
  • Q2 NGENLA/Genotropin profit share was $6.1 million; mgmt attributes Q2 gross-to-net benefit to prior-quarter co-pay assistance carryover.
  • Diagnostics segment Q2 operating loss was $18.2 million, including $2 million nonrecurring, $4.5 million from oncology business (closing later in 2025), and $4.9 million D&A, yielding ~$6 million monthly loss.
  • 4Kscore test sales up ~12% YTD (July acceleration before FDA label change); primary-care expansion expected to drive further growth.
• Mgmt stance: bullish — optimistic on NGENLA prescription trends across all geographies; on track for Diagnostics cash-flow positive in 2025 after oncology close.

Q2 — Edward Andrew Tenthoff

• Topic: Oxyntomodulin differentiation in obesity/MASH & Phase I trial design
• Key points:
  • Differentiation via glucagon-driven FGF21 increase (anti-fibrotic effect) for MASH patients; oral formulation with Entera offers stabilization/maintenance after injectable phase.
  • Phase I will target patients with biomarker evidence of MASH (liver stiffness, liver fat) and obesity; no biopsy study; focus on safety, dosing, and biomarker trends.
  • Development is expensive; mgmt anticipates potential collaborations after Phase I data.
• Mgmt stance: neutral to bullish — biological differentiation and oral option are advantages, but Phase I outcomes are unproven; will seek partners.

Q3 — I-Eh Jen

• Topic: Phase I patient population for dual agonist & short bowel syndrome program timeline
• Key points:
  • Phase I targets F2–F4 MASH patients with obesity; estimated enrollment 100–170 patients; starts late 2025 or early 2026.
  • Short bowel syndrome compound (GLP-2) is separate from GLP-1/glucagon agonist; targets unmet need in intestinal absorption/malnutrition.
  • Oral version of GLP-1/glucagon agonist with Entera is in development; timeline for short bowel program is "definitely next year" (2026).
• Mgmt stance: neutral — Phase I size/design defined, but exact start depends on FDA/regulatory; separate programs have different patient populations.

Q4 — Yi Chen

• Topic: GLP-1/glucagon dual agonist's potential to mitigate GI side effects and lean muscle loss
• Key points:
  • Mgmt cannot confirm superior GI tolerability; titrating properly is key; preclinical data show "very good profile," but differences across molecules.
  • On lean muscle mass: glucagon may enhance metabolism, but no definitive answer; other trials (e.g., Boehringer Ingelheim) show "a little bit better profile," but mgmt will not commit.
• Mgmt stance: cautious — no guarantee of improved side-effect or muscle-loss profile vs. existing GLP-1 drugs; hopes based on metabolic differences.

Q5 — Michael John Petusky

• Topic: BARDA revenue, cash flow breakeven assumptions, capital allocation priorities
• Key points:
  • Q2 BARDA revenue: $6.5 million; full-year 2025 BARDA guidance: $30 million–$35 million.
  • Post-oncology close, annualized revenue ~$300 million; cash flow breakeven does not require revenue growth, though growth plan exists.
  • H1 2025: ~$100 million invested in R&D; ~$80 million deployed in share buybacks/debt exchanges; $141.5 million remaining under $200 million board authorization.
  • Forward capital allocation: slower pace expected; seeking non-dilutive partnership funding for R&D programs.
• Mgmt stance: neutral to bullish — balance sheet supports buybacks; confident in achieving cash profitability without top-line growth; opportunistic on buybacks.